A new review published by Cochrane has stirred debate about the effectiveness of Alzheimer's drugs. The analysis concluded that the clinical benefit of anti-amyloid drugs is negligible, but many experts criticized the review for lumping failed drugs with recently approved treatments like Leqembi and Kisunla.

The review evaluated studies conducted on seven monoclonal antibody drugs developed over the last two decades to target amyloids. Some Alzheimer's experts said the conclusions were meaningless because the review mixed drugs that had shown very dissimilar results and worked differently.

Dr. Jason Karlawish, a director of the Penn Memory Center at the University of Pennsylvania, said the review took some rotten ingredients and mixed them with fresh food, resulting in a stinky stew. The review looked at 17 studies conducted from 2014 to 2024 and funded by drug companies.